Search research articles
Contact Us
Filters
Showing results (561-570 of 692) with videos related to
Page
of 70
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Luis Paz-Ares, Vera Hirsh, Li Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 4, 2019
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
B C M Hermans, J L Derks, E Thunnissen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Enriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Future Oncology (London, England)
|
December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistance
Egbert F Smit, Christophe Dooms, Jo Raskin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2002
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors
Bart C Kuenen, Lee Rosen, Egbert F Smit, et al.
Virchows Archiv : an International Journal of Pathology
|
April 4, 2013
Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus
Johannes L Blaauwgeers, Ingrid Kappers, Houke M Klomp, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
September 12, 2014
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology
Daoud Sie, Peter J F Snijders, Gerrit A Meijer, et al.
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Thorax
|
November 15, 2013
DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer
Robert A A van Boerdonk, Johannes M A Daniels, Peter J F Snijders, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 16, 2020
Quantification of PD-L1 Expression with <sup>18</sup>F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Marc C Huisman, Anna-Larissa N Niemeijer, Albert D Windhorst, et al.
Page
of 70
Search research articles
Search
Showing results (561-570 of 692) with videos related to
Sort By:
Page
of 70
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Luis Paz-Ares, Vera Hirsh, Li Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 4, 2019
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
B C M Hermans, J L Derks, E Thunnissen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Enriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Future Oncology (London, England)
|
December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistance
Egbert F Smit, Christophe Dooms, Jo Raskin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2002
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors
Bart C Kuenen, Lee Rosen, Egbert F Smit, et al.
Virchows Archiv : an International Journal of Pathology
|
April 4, 2013
Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus
Johannes L Blaauwgeers, Ingrid Kappers, Houke M Klomp, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
September 12, 2014
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology
Daoud Sie, Peter J F Snijders, Gerrit A Meijer, et al.
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Thorax
|
November 15, 2013
DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer
Robert A A van Boerdonk, Johannes M A Daniels, Peter J F Snijders, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 16, 2020
Quantification of PD-L1 Expression with <sup>18</sup>F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Marc C Huisman, Anna-Larissa N Niemeijer, Albert D Windhorst, et al.
Page
of 70